There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ocugen (OCGN – Research Report) and Xilio ...
This week, one Waltham biotech announced a deal to work with AbbVie that will pay out $52M upfront, while another one made ...
AbbVie has entered a partnership and option-to-license agreement with Xilio Therapeutics to develop new tumour-activated, ...
The Dow Jones index dropped 400 points on Wednesday, February 12 as US Inflation data dimmed Federal Reserve rate cuts hopes ...
Stock Market Today saw a sharp decline as the Dow Jones plummeted 400 points following a rise in US Inflation to 3% YoY. The ...
Shares in biotech group Xilio Therapeutics (XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie ...
AbbVie and Xilio Therapeutics are partnering to make “masked” T cell engagers, which they hope will be safer than currently available options.
AbbVie Inc (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO) announced a collaboration and option-to-license agreement to ...
US pharma major AbbVie has announced a deal with Xilio Therapeutics, more than doubling the latter’s share price.
AbbVie (NYSE: ABBV) and Xilio Therapeutics, Inc. (NASDAQ: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback